Monoclonal antibodies targeting CCL2 have been shown to effectively reduce macrophage accumulation in preclinical tumor models and enhance anti-tumor efficacy when combined with conventional chemotherapy [421,422]. This evidence concerns the gene CCL2 and neoplasm.